WHO Leads Effort To Build R&D Roadmap For Future Epidemics

Panel Chair Barbara Stocking, photo credit John Zaracostas

The World Health Organization is working to learn from the fast response on research and development for Ebola that led to effective treatments in a short time. It hopes that this changes the way R&D for emergency vaccines is done forever.

Polish Government Drafts IP Law Reform

Polish_Patent_Office_sculpture

WARSAW — More than twenty years after Poland’s parliament passed the Authors’ and Related Rights law of 1994, the Polish government is drafting three bills to modify the country’s intellectual property legislation. The first of the drafts prepared by the Polish Ministry of Culture and National heritage was submitted to the Parliament in March, and is currently being deliberated, while the ministry is finishing work on the remaining two drafts.

In ‘Huge’ Move, WHO Adds Key Hepatitis C, Cancer, TB Drugs To Essential Medicines List

happy crowd africa

The World Health Organization today published its updated Model List of Essential Medicines, including high-priced new treatments for hepatitis C, cancers and multi-drug resistant tuberculosis (MDR-TB) that were quickly applauded by the public health advocacy community.

EU Trade Commissioner New Paper On Investor-State Disputes In TTIP

Malmstrom shot

EU Trade Commissioner Cecilia Malmström published a concept paper on investor-state dispute settlement (ISDS) mechanisms to be included in the Trans-Atlantic Trade and Investment Partnership (TTIP).

Industry Asks For Clarity On LDC Request To Extend TRIPS Pharma Waiver

medicines for poor

Least developed countries (LDCs) at the World Trade Organization have requested that a waiver allowing them to not enforce intellectual property rights on pharmaceutical products be extended beyond its deadline of 1 January 2016. The brand pharmaceutical industry this week stated that it supports access to medicines for LDCs but does not see the need for this extension as LDCs already benefit from a WTO waiver on all products until 2021.

Pharma Offers View On How To Slow Antimicrobial Resistance, Boost Research

Bacteria

the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) provided its recommendations on how to slow down antimicrobial resistance and boost antibiotic research and development. In addition, the association organised a forum on the subject today.

Chile: Study On Pharma Patents Shows Foreign Ownership

pills

In Chile, pharmaceutical patents are almost exclusively the domain of foreign companies. Only a subset of drugs is protected by patents, while a much larger number of products is protected by trademarks, a study finds, offering for the first time empirical evidence on the use of primary and secondary patents in Chile.

Philanthropies And Expression: An Interview With Ford Foundation President Darren Walker

Darren Walker

Darren Walker is president of the Ford Foundation, one of the largest and historically most influential private philanthropies in the United States, dedicated to human welfare worldwide. Among its areas of focus are programs on freedom of expression and internet rights, extremely timely given current national and global events. Ford, along with four other leading foundations, and leaders from government, business and the technology community recently announced NetGain, a partnership to “spark the next generation of innovation for social change and progress.” Intellectual Property Watch’s William New recently interviewed Darren Walker on his vision for the foundation, internet governance, and the world at large.

WHO: Too Few Countries Fighting Antimicrobial Resistance; Global Action Plan Advocates Equitable Access

Antibiotics

The World Health Organization released a report today on countries’ response to the global declining effect of antibiotics on bacteria and microbes, heightened by overuse or misuse of those products. Next month the World Health Assembly will consider a draft global action plan to fight the problem, which includes suggestions for sustainable investment in the area such as de-linking research from price and sales, as well as equitable access to new products.